Route of administration other than oral for concomitant me­di­cation [Bioanalytics]

posted by Ohlbe – France, 2020-02-05 10:13  – Posting: # 21147
Views: 459

Dear Qualityassurance,

» Can anyone suggest me :confused::confused: if it is required to include these medications in concomitant medication experiment if the route of administration is other than oral (e.g. IV, topical, eye drops) during clinical phase?

I would say it depends on the bioavailability of these products when administered by these routes. For IV, no discussion (at least, if there is an active substance - don't bother about saline or glucose). But for a topical administration the answer is likely that there is no point.

Regards
Ohlbe

Complete thread:

Activity
 Admin contact
20,477 posts in 4,300 threads, 1,415 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time (Europe/Vienna): 21:01 CEST

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5